Welcome to our dedicated page for HSDTW SEC filings (Ticker: HSDTW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Solana Company filings document a Delaware public company’s material-event disclosures, annual proxy matters and capital-structure actions. Recent Form 8-K reports cover unregistered sales of equity securities, terms announced for a registered direct offering, board composition changes, director appointments, an executive separation agreement and related exhibits.
Its definitive proxy materials disclose director and governance matters, executive compensation, equity-award valuation data, pay-versus-performance tables and stockholder meeting items. The filings also identify the company’s registered Class A common stock and Nasdaq listing information for that class.
Solana Company announced that Antonella Favit‑Van Pelt, MD, PhD, has mutually agreed with the company to resign as Chief Medical Officer, effective April 8, 2026. The parties entered into a Separation Agreement effective the same date.
Under this agreement, Dr. Favit‑Van Pelt will receive a lump‑sum separation payment of $875,000, less applicable withholdings, to be paid within ten business days after the effective date. In return, she waives and releases employment‑related claims and must continue to honor confidentiality and invention assignment obligations from her employment agreement.
Solana Company announced that Antonella Favit‑Van Pelt, MD, PhD, has mutually agreed with the company to resign as Chief Medical Officer, effective April 8, 2026. The parties entered into a Separation Agreement effective the same date.
Under this agreement, Dr. Favit‑Van Pelt will receive a lump‑sum separation payment of $875,000, less applicable withholdings, to be paid within ten business days after the effective date. In return, she waives and releases employment‑related claims and must continue to honor confidentiality and invention assignment obligations from her employment agreement.
Solana Company is soliciting proxies for its 2026 Annual Meeting of Stockholders, to be held virtually on May 21, 2026 at 9:00 a.m. ET. Holders of its Class A common stock as of April 1, 2026, when 54,889,569 shares were outstanding, may vote.
Stockholders will elect seven directors and vote on ratifying CBIZ as independent registered public accounting firm for the year ending December 31, 2026. The board recommends voting FOR all director nominees and FOR Proposal 2.
The filing details board independence, leadership structure and committee assignments, and outlines executive pay. In 2025, CEO Dane Andreeff received total compensation of $2.1 million, CFO Jeffrey Mathiesen received $1.5 million, and Executive Chairman Joseph Chee received $6.9 million, including 1,109,118 RSUs tied to a 2025 private placement and digital asset treasury work. The proxy also describes change-in-control severance protections, a clawback policy for erroneously awarded compensation, and the company’s insider trading and board governance policies.
Solana Company is soliciting proxies for its 2026 Annual Meeting of Stockholders, to be held virtually on May 21, 2026 at 9:00 a.m. ET. Holders of its Class A common stock as of April 1, 2026, when 54,889,569 shares were outstanding, may vote.
Stockholders will elect seven directors and vote on ratifying CBIZ as independent registered public accounting firm for the year ending December 31, 2026. The board recommends voting FOR all director nominees and FOR Proposal 2.
The filing details board independence, leadership structure and committee assignments, and outlines executive pay. In 2025, CEO Dane Andreeff received total compensation of $2.1 million, CFO Jeffrey Mathiesen received $1.5 million, and Executive Chairman Joseph Chee received $6.9 million, including 1,109,118 RSUs tied to a 2025 private placement and digital asset treasury work. The proxy also describes change-in-control severance protections, a clawback policy for erroneously awarded compensation, and the company’s insider trading and board governance policies.
Solana Company appointed Agustina “Madelene” Gani Tjandrasuwita as Chief Operating Officer and Deputy Chief Financial Officer, effective April 6, 2026. She brings more than 25 years of global finance experience across crypto, fintech, and public companies, including senior roles at Hedera Hashgraph, Aptos Labs, Gemini, and JUUL Labs.
Under an Offer Letter dated March 13, 2026, she will receive a $350,000 annual base salary, be eligible for an annual target bonus equal to 40% of base salary, and additional equity incentives with a combined target value of $300,000 to $500,000. After three months, subject to board approval, she is also eligible for a one-time stock option grant with a grant date fair value of $75,000, vesting over four years.
Solana Company appointed Agustina “Madelene” Gani Tjandrasuwita as Chief Operating Officer and Deputy Chief Financial Officer, effective April 6, 2026. She brings more than 25 years of global finance experience across crypto, fintech, and public companies, including senior roles at Hedera Hashgraph, Aptos Labs, Gemini, and JUUL Labs.
Under an Offer Letter dated March 13, 2026, she will receive a $350,000 annual base salary, be eligible for an annual target bonus equal to 40% of base salary, and additional equity incentives with a combined target value of $300,000 to $500,000. After three months, subject to board approval, she is also eligible for a one-time stock option grant with a grant date fair value of $75,000, vesting over four years.
Solana Co officer Tjandrasuwita Agustina Gani, listed as COO & Deputy CFO, has filed an insider ownership report for the company. The filing shows no insider stock transactions or derivative positions, indicating only the reporting of status as an officer without buy or sell activity.
Solana Co officer Tjandrasuwita Agustina Gani, listed as COO & Deputy CFO, has filed an insider ownership report for the company. The filing shows no insider stock transactions or derivative positions, indicating only the reporting of status as an officer without buy or sell activity.
Solana Co director Sherrie L. Perkins reported equity compensation awards. She received a stock option covering 23,529 shares of Class A Common Stock at an exercise price of $6.881 per share, expiring on March 30, 2036. She was also granted 2,180 shares of Class A Common Stock as restricted stock units under the 2022 Equity Incentive Plan. According to the awards’ terms, 75% of both the RSUs and options vested on March 31, 2026, with the remaining 25% scheduled to vest on June 30, 2026, subject to her continued service. Following the stock grant, she directly holds 92,220 shares of Class A Common Stock.
Solana Co director Sherrie L. Perkins reported equity compensation awards. She received a stock option covering 23,529 shares of Class A Common Stock at an exercise price of $6.881 per share, expiring on March 30, 2036. She was also granted 2,180 shares of Class A Common Stock as restricted stock units under the 2022 Equity Incentive Plan. According to the awards’ terms, 75% of both the RSUs and options vested on March 31, 2026, with the remaining 25% scheduled to vest on June 30, 2026, subject to her continued service. Following the stock grant, she directly holds 92,220 shares of Class A Common Stock.
Solana Co director Paul Buckman received new equity awards as part of his compensation. He was granted a stock option covering 23,529 shares of Class A Common Stock at an exercise price of $6.881 per share, expiring on March 30, 2036.
He also received 2,180 shares of Class A Common Stock, increasing his direct holdings to 92,004 shares. Both the option and restricted stock units vest 75% on March 31, 2026, with the remaining 25% scheduled to vest on June 30, 2026, contingent on his continued service.
Solana Co director Paul Buckman received new equity awards as part of his compensation. He was granted a stock option covering 23,529 shares of Class A Common Stock at an exercise price of $6.881 per share, expiring on March 30, 2036.
He also received 2,180 shares of Class A Common Stock, increasing his direct holdings to 92,004 shares. Both the option and restricted stock units vest 75% on March 31, 2026, with the remaining 25% scheduled to vest on June 30, 2026, contingent on his continued service.
Solana Co director Walter Blane received new equity awards in the form of stock options and restricted stock units. He was granted stock options covering 23,529 shares of Class A Common Stock at an exercise price of $6.881 per share, expiring on March 30, 2036. He also received 2,180 shares of Class A Common Stock from a grant classified as a restricted stock unit award. According to the award terms, 75% of both the RSUs and the options vested on March 31, 2026, with the remaining 25% scheduled to vest on June 30, 2026, if he continues in service.
Solana Co director Walter Blane received new equity awards in the form of stock options and restricted stock units. He was granted stock options covering 23,529 shares of Class A Common Stock at an exercise price of $6.881 per share, expiring on March 30, 2036. He also received 2,180 shares of Class A Common Stock from a grant classified as a restricted stock unit award. According to the award terms, 75% of both the RSUs and the options vested on March 31, 2026, with the remaining 25% scheduled to vest on June 30, 2026, if he continues in service.
Solana Company (HSDT) has transformed into a listed digital asset treasury focused on acquiring and holding Solana tokens (SOL), aiming to maximize SOL per share through capital markets activity, staking and selective DeFi strategies. The treasury is expected to remain highly concentrated in SOL, with significant portions staked via institutional custodians and validators to earn yield, while managing liquidity through unstaked SOL, liquid staking tokens, cash and stablecoins.
The company also maintains, to a lesser extent, its legacy neurotechnology business built around the PoNS medical device, which is cleared or authorized for multiple gait and balance indications in the U.S. and Canada and has been commercially available in those markets for several years.
Solana Company (HSDT) has transformed into a listed digital asset treasury focused on acquiring and holding Solana tokens (SOL), aiming to maximize SOL per share through capital markets activity, staking and selective DeFi strategies. The treasury is expected to remain highly concentrated in SOL, with significant portions staked via institutional custodians and validators to earn yield, while managing liquidity through unstaked SOL, liquid staking tokens, cash and stablecoins.
The company also maintains, to a lesser extent, its legacy neurotechnology business built around the PoNS medical device, which is cleared or authorized for multiple gait and balance indications in the U.S. and Canada and has been commercially available in those markets for several years.
Kathmere Capital Management, LLC reported beneficial ownership of 4,594,960 shares of Class A Common Stock of Solana Co, equal to 8.7% of the class as of 02/24/2026. The filing lists Kathmere with sole dispositive power over 4,594,960 shares and no voting power reported.
Kathmere Capital Management, LLC reported beneficial ownership of 4,594,960 shares of Class A Common Stock of Solana Co, equal to 8.7% of the class as of 02/24/2026. The filing lists Kathmere with sole dispositive power over 4,594,960 shares and no voting power reported.
Solana Company, formerly known as Helius Medical Technologies, Inc., reported its current capital structure. As of February 20, 2026, the Company has 52,802,604 shares of common stock issued and outstanding. In addition, it has pre-funded warrants outstanding that are exercisable for 23,930,181 shares of common stock.
Solana Company, formerly known as Helius Medical Technologies, Inc., reported its current capital structure. As of February 20, 2026, the Company has 52,802,604 shares of common stock issued and outstanding. In addition, it has pre-funded warrants outstanding that are exercisable for 23,930,181 shares of common stock.